Menu Search
Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Learn moreSubscribe now
Equities

Vimian Group AB

0V0:DUS

Vimian Group AB

Actions
  • Price (EUR)3.71
  • Today's Change-0.02 / -0.54%
  • Shares traded30.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 01 2024 18:31 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Vimian Group AB is a Sweden-based veterinary company. The Company is a parent company of the group of companies operating with a purpose of improving animal health through science and technology. The Group delivers solutions to veterinary professionals, labs and pet parents around the world. The purpose of Vimian Group is to unite companies in selected niches of animal health and help them grow faster. The Company invests in innovation and new technologies to advance veterinary medicine. The Group covers four essential and rapidly evolving areas within animal health: Specialty Pharma, Diagnostics, Veterinary Services and MedTech. Vimian provides individual businesses with access to its networks, advisory services, infrastructure and capital.

  • Revenue in SEK (TTM)4.08bn
  • Net income in SEK2.96m
  • Incorporated2020
  • Employees1.10k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		VIMIAN:STO since
announced		Transaction
value
iM3 Dental LtdAnnounced06 Sep 202406 Sep 2024Announced2.21%--
Data delayed at least 15 minutes, as of Nov 01 2024 12:30 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.